Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

MilliporeSigma Opens Viral Clearance Lab in Shanghai, Part of a $29 Million Project

publication date: Sep 23, 2022

MilliporeSigma, a Merck KGaA subsidiary, opened a viral clearance laboratory in Shanghai as part of the first building phase of its new $29 million China Biologics Testing Center. The 53,000 square foot center is MilliporeSigma’s first such facility in China. The VC laboratory allows customers to conduct viral clearance studies in China from pre-clinical development to commercialization, a service that is increasing at a double-digit rate in China. The facility’s second phase, which is expected to open in late 2023, will offer cell line characterization and lot release testing services. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital